![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » MYLAN LABS BUYS MAJORITY STAKE IN MATRIX LABS
MYLAN LABS BUYS MAJORITY STAKE IN MATRIX LABS
August 28, 2006
Global generics major Mylan Laboratories has announced it will acquire up to 71.5 percent of Mumbai-based API manufacturer Matrix's shares outstanding for $6.5 per share. Under the terms of the transaction, Mylan will purchase 51.5 percent of Matrix's shares outstanding pursuant to an agreement with certain selling shareholders and will make an "open offer" to Matrix's remaining shareholders to acquire up to an additional 20 percent of Matrix's shares outstanding. BioSpectrum (http://www.biospectrumasia.com/content/280806IND1451.asp)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct